Get the Stockscreener App
4.56
2.47%
0.11
After Hours:
4.37
-0.19
-4.17%
Taysha Gene Therapies Inc stock is traded at $4.56, with a volume of 5.66M.
It is up +2.47% in the last 24 hours and down -4.80% over the past month.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$4.45
Open:
$4.55
24h Volume:
5.66M
Relative Volume:
2.05
Market Cap:
$1.25B
Revenue:
$6.31M
Net Income/Loss:
$-99.93M
P/E Ratio:
-12.87
EPS:
-0.3544
Net Cash Flow:
$-85.14M
1W Performance:
-1.08%
1M Performance:
-4.80%
6M Performance:
+61.13%
1Y Performance:
+149.18%
1-Day Range:
$4.31
$4.66
1-Week Range:
$4.31
$4.715
52-Week Range:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.56 | 1.22B | 6.31M | -99.93M | -85.14M | -0.3544 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Raymond James | Strong Buy |
| Jul-11-25 | Initiated | BofA Securities | Buy |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Decoding Taysha Gene Therapies Inc (TSHA): A Strategic SWOT Insi - GuruFocus
Taysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advances - MSN
Taysha Gene Therapies Q4 Loss Of US$27.9m Tests Bullish TSHA 102 Narrative - simplywall.st
Taysha Gene Therapies Signals Momentum in Earnings Call - TipRanks
Taysha Gene Therapies (TSHA) Advances Rett Syndrome Treatment - GuruFocus
Key facts: Taysha $109M loss; Q4 rev +171%; $320M cash; TSHA-102 safe, Q2'26 - TradingView
TSHA: Analyst Chardan Capital Maintains Buy Rating with $12 PT | - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Australia
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlight - GuruFocus
Taysha Gene Therapies, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies’ Q4 Earnings Call: FDA Timeline, European Strategy Claims Don’t Match Prior Statements - Bitget
Taysha (TSHA) Reports Strong Q4 Revenue and Promising Progress i - GuruFocus
Taysha Gene Therapies Q4 Earnings Call Highlights - Yahoo Finance
Taysha Gene Therapies 2026 Conference Call: TSHA-102 Development & Regulatory PlansNews and Statistics - IndexBox
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update - Investing News Network
TSHA: TSHA-102 advanced toward registration with strong trial data, FDA alignment, and solid cash runway - TradingView
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Taysha (TSHA) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Taysha (TSHA) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Taysha Gene Therapies Q4 2025 sees widened loss - Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Valuation Update: How correlated is Taysha Gene Therapies Inc to the S P5002026 Price Momentum & Daily Oversold Bounce Ideas - baoquankhu1.vn
Taysha Gene Therapies, Inc. Appoints Brad Martin as Senior Vice President, Market Access and Value - marketscreener.com
Taysha (TSHA) Reports Strong Q4 Revenue and Promising Progress in Trials - GuruFocus
Taysha Gene Therapies 10-K: $9.8M Revenue, $(0.34) EPS - TradingView
Rett gene therapy advances at Taysha Gene Therapies (TSHA) - Stock Titan
Taysha Gene Therapies reports full-year 2025 earnings and issues corporate update - Traders Union
Earnings Flash (TSHA) Taysha Gene Therapies Posts 2025 Net Loss $0.34 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Taysha Gene Therap Reports 2025 Full-Year Results — $9.8M Revenue, $109.0M Net Loss - TradingView
Taysha Gene Therapies (TSHA) deepens 2025 loss but advances Rett trial - Stock Titan
TSHA: TSHA-102 trials progressed with strong safety, regulatory alignment, and robust cash position - TradingView
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Needham Maintains Taysha Gene Therapies (TSHA) Buy Recommendation - MSN
Ally Bridge Group NY LLC Acquires Shares of 1,898,112 Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19 - The Manila Times
Taysha Gene Therapies Inc. (TSHA): A promising biotech on Rett syndrome drug prospects - MSN
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade - MSN
Jefferies Financial Group Inc. Sells 8,157,091 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
B of A Securities Initiates Coverage of Taysha Gene Therapies (TSHA) with Buy Recommendation - MSN
Aug Catalysts: How cyclical is Taysha Gene Therapies Incs revenue streamDividend Hike & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug Reactions: What hedge funds are buying Taysha Gene Therapies IncTrade Risk Report & Weekly Hot Stock Watchlists - baoquankhu1.vn
Decliners Report: Is Taysha Gene Therapies Inc stock good for income investors2025 Winners & Losers & Weekly Top Performers Watchlists - baoquankhu1.vn
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies (TSHA) Grants Stock Units and Options to N - GuruFocus
Taysha Gene Therapies announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Highs Report: Is Taysha Gene Therapies Inc attractive for institutional investorsTrade Entry Summary & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Aug Update: Will Taysha Gene Therapies Inc benefit from AI trendsJuly 2025 Recap & Fast Gain Swing Trade Alerts - baoquankhu1.vn
TSHA SEC FilingsTaysha Gene Therapies, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):